Patent intelligence · US
US 6884239
Ingestible device for the release of substances at distinct locations in alimentary canal
Ingestible device for the release of substances at distinct locations in alimentary canal
Patent details — US 6884239
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 26, 2005
- Expiration
- Apr 21, 2025
- Applicant
- Phaeton Research Ltd.
- Claims
- 19
- CPC classes
- A61P, A61P1/00
Quick answer
US 6884239 (Ingestible device for the release of substances at distinct locations in alimentary canal) is held by Phaeton Research Ltd.. Status: expired. Granted Apr 26, 2005. Expires Apr 21, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Phaeton Research Ltd.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61P, A61P1/00
More from Phaeton Research Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12419831
Hydrocortisone oral liquid formulations
granted -
US 12396974
Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
granted -
US 12357582
Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
granted -
US 12343324
Dihydromyricetin hot melt extrusion formulations and methods for forming them
granted -
US 12329816
Immunotherapy with metabolic enzyme expression
granted -
US 12209256
System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction
granted -
US 12195768
System and method for modulating stress granule assembly
granted -
US 12186436
Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
granted
Frequently asked questions
What is US patent 6884239?
US 6884239 (Ingestible device for the release of substances at distinct locations in alimentary canal) is held by Phaeton Research Ltd.. Status: expired. Granted Apr 26, 2005. Expires Apr 21, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6884239?
Phaeton Research Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 163 pharmaceutical patents for this assignee.
When does US 6884239 expire?
Our index shows an expiration date of Apr 21, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.